A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug

Brief description of study

This is a Phase 3 multicenter study that includes two periods. Period 1 is designed to
compare the safety, tolerability, and efficacy of ABT-494 Dose A once daily (QD) and Dose B
QD versus placebo and versus adalimumab every other week (eow) in participants with
moderately to severely active Psoriatic Arthritis (PsA) and have an inadequate response to
non-biologic DMARDs (DMARD-IR). Period 1 is also designed to compare the efficacy of ABT-494
Dose A QD and Dose B QD versus placebo for the prevention of structural progression. Period 2
evaluates the safety, tolerability and efficacy of ABT-494 Dose A QD and Dose B QD in
participants with PsA who have completed Period 1.